1. Home
  2. Labeler Index
  3. Bryant Ranch Prepack
  4. 71335-0748
  5. Product Images: Levetiracetam

Product Images Levetiracetam

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 11 images provide visual information about the product associated with Levetiracetam NDC 71335-0748 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 02

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 02

This text provides a formula for estimating creatinine clearance, which is an important indicator of kidney function. The formula uses the patient's age and weight, along with their serum creatinine level, to calculate an estimate of their creatinine clearance. The formula adjusts for gender, with a lower factor used for female patients.*

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 03

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 03

Levetiracetam Structural Formula - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 04

Levetiracetam Structural Formula - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 04

Figure 1: Responder Rate (greater than or equal to 50% Reduction from Baseline) in Study 1 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 05

Figure 1: Responder Rate (greater than or equal to 50% Reduction from Baseline) in Study 1 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 05

The text provides a graph titled Figure 1 showing the Responder Rate (>50% Reduction From Baseline) In Study 1. The graph showcases that Levetiracetam medication can reduce more than 50% of the baseline in patients compared to Placebo, which is not that effective. The Levetiracetam medication dosage was 1000 mg/day for one group of patients (N=37) and 3000 mg/day for another group of patients (N=101). The former group's data shows 39.6% response rate, whereas the latter group's data shows a 37.1% response rate. There was a significant difference found in one group's data, as they achieved statistically significant results against Placebo.*

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 06

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 06

The text describes Figure 2 which shows the responder rate (>50% reduction from baseline) in Study 2, Period A. The figure includes a graph with percentages and different treatment groups including a placebo group and two groups taking different doses of Levetiracetam. The asterisk indicates statistical significance versus placebo.*

Figure 3: Responder Rate (greater than or equal to 50% Reduction from Baseline) in Study 3 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 07

Figure 3: Responder Rate (greater than or equal to 50% Reduction from Baseline) in Study 3 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 07

This figure represents the responder rate, which is defined as the percentage of patients who experienced greater than 50% reduction from their baseline seizure frequency. The study included a placebo group (N=104) and a group who received levetiracetam at a dose of 3000 mg/day (N=180). The graph shows that the responder rate was significantly higher in the group treated with levetiracetam compared to the placebo group.*

Figure 4: Responder Rate (greater than or equal to 50% Reduction from Baseline) - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 08

Figure 4: Responder Rate (greater than or equal to 50% Reduction from Baseline) - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 08

The text describes a graph labeled "Figure 4" that shows the responder rate in a study referred to as "Study 4". The graph displays percentages from 5% to 50% and shows two groups: a placebo group with 97 patients and a Levetiracetam group with 101 patients. The text indicates that the Levetiracetam group had a statistically significant reduction in responder rate compared to the placebo group. There is no information on what condition or disease the study relates.*

figure 5 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 09

figure 5 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 09

Figure 6: Responder Rate (greater than or equal to 50% Reduction from Baseline) in PGTC Seizure Frequency per Week - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 10

Figure 6: Responder Rate (greater than or equal to 50% Reduction from Baseline) in PGTC Seizure Frequency per Week - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 10

The provided text describes the responder rate of patients with PGTC seizures in Study 7. The graph in Figure 6 shows the percentage of patients who achieved a 50% reduction from baseline in seizure frequency per week. Levetiracetam was found to be statistically significant compared to placebo in this study.*

image 01

image 01

Label Image - lbl713350748

Label Image - lbl713350748

This is a package of Keppra 500mg Tablet, manufactured by Zhejiang Huahai Pharma Co Ltd, and packaged by Bryant Ranck Prepack. The package contains 90 tablets and expires on the month and year stated as MM/YY. The NDC code is 7133507481. The address of the manufacturer is not mentioned. The storage instructions state to keep the package at a room temperature of 20°C to 25°C (68°F to 77°F). The last number sequence might be a barcode.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.